Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H20N2O |
Molecular Weight | 268.3535 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1)C2=CC=CC=C2N3CCNCC3
InChI
InChIKey=GJCDKKZASRZMHC-UHFFFAOYSA-N
InChI=1S/C17H20N2O/c1-20-15-8-6-14(7-9-15)16-4-2-3-5-17(16)19-12-10-18-11-13-19/h2-9,18H,10-13H2,1H3
Molecular Formula | C17H20N2O |
Molecular Weight | 268.3535 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22738316Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23830697
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22738316
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23830697
LP-20 (1-[2-(4-Methoxyphenyl)phenyl]piperazine) is a potent serotonin 5-HT7 receptor antagonist with a low binding affinity for the 5-HT1A and adrenergic 1 receptor. In animal models
LP-20 was investigated as a potential positron emission tomography (PET) radiotracer, due to high synthetic availability of 11C radiolabeled compound. Although [11C] LP-20 exhibited in vitro binding with 5-HT7, moderate brain uptake and relatively stable metabolism in the brain, in vivo evaluation showed limited specificity of [11C] LP-20 for 5-HT7.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3155 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22738316 |
2.6 nM [Ki] | ||
Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22738316 |
476.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23830697
Rats was treated i.v. with [11C]4 (LP-20) (16–18 MBq/200 lL, 0.07–0.11 nmol) as a single dose.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23830697
Four rat brains were quickly removed and frozen on powdered dry ice. Sagittal sections (20 mkM) of the brain were cut using a cryostat microtome (HM560; Carl Zeiss, Germany) and thaw mounted on glass slides, which were then dried and stored at -80 C until use. Brain sections were preincubated (3 x 5 min) in Tris–HCl (50 mM, pH 7.4) at room temperature. After preincubation, these sections were incubated for 30 min at room temperature in fresh buffer with [11C]4 (LP-20) (1 nM, 37 MBq/200 mL). Unlabeled LP-20 (1 mkM) was used to elucidate the specific binding of [11C]4 (LP-20) for 5-HT7. After incubation, the sections were washed (3 x 5 min) with cold buffer, dipped in cold distilled water, and dried with cold air. These sections were placed in contact with imaging plates (BAS-MS2025; FUJIFILM, Tokyo, Japan). Autoradiograms were obtained and photo-stimulated luminescence values (PSL) in the regions of interest (ROIs) were measured using a Bio- Imaging Analyzer System (BAS5000, FUJIFILM)
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:58:30 GMT 2023
by
admin
on
Sat Dec 16 07:58:30 GMT 2023
|
Record UNII |
3RQ1LHQ82N
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3RQ1LHQ82N
Created by
admin on Sat Dec 16 07:58:30 GMT 2023 , Edited by admin on Sat Dec 16 07:58:30 GMT 2023
|
PRIMARY | |||
|
22001618
Created by
admin on Sat Dec 16 07:58:30 GMT 2023 , Edited by admin on Sat Dec 16 07:58:30 GMT 2023
|
PRIMARY | |||
|
3RQ1LHQ82N
Created by
admin on Sat Dec 16 07:58:30 GMT 2023 , Edited by admin on Sat Dec 16 07:58:30 GMT 2023
|
PRIMARY | |||
|
1386927-90-7
Created by
admin on Sat Dec 16 07:58:30 GMT 2023 , Edited by admin on Sat Dec 16 07:58:30 GMT 2023
|
PRIMARY | |||
|
2048034
Created by
admin on Sat Dec 16 07:58:30 GMT 2023 , Edited by admin on Sat Dec 16 07:58:30 GMT 2023
|
ALTERNATIVE | |||
|
1594338
Created by
admin on Sat Dec 16 07:58:30 GMT 2023 , Edited by admin on Sat Dec 16 07:58:30 GMT 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |